IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Identifieur interne : 002C78 ( Main/Exploration ); précédent : 002C77; suivant : 002C79IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Auteurs : Michele W L. Teng [Australie] ; Edward P. Bowman [États-Unis] ; Joshua J. Mcelwee [États-Unis] ; Mark J. Smyth [Australie] ; Jean-Laurent Casanova [France] ; Andrea M. Cooper [États-Unis] ; Daniel J. Cua [États-Unis]Source :
- Nature medicine [ 1546-170X ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Humains, Immunité, Inflammation (anatomopathologie), Inflammation (immunologie), Interleukine-12 (antagonistes et inhibiteurs), Interleukine-12 (métabolisme), Interleukine-23 (antagonistes et inhibiteurs), Interleukine-23 (métabolisme), Surveillance immunologique, Thérapie moléculaire ciblée.
- MESH :
- anatomopathologie : Inflammation.
- antagonistes et inhibiteurs : Interleukine-12, Interleukine-23.
- immunologie : Inflammation.
- métabolisme : Interleukine-12, Interleukine-23.
- Animaux, Humains, Immunité, Surveillance immunologique, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Interleukin-12, Interleukin-23.
- immunology : Inflammation.
- chemical , metabolism : Interleukin-12, Interleukin-23.
- pathology : Inflammation.
- Animals, Humans, Immunity, Immunologic Surveillance, Molecular Targeted Therapy.
Abstract
The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell-mediated responses in inflammation for more than a decade after it was first identified. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Ustekinumab, a therapeutic agent targeting both cytokines, was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders. Here we discuss the therapeutic rationale for targeting these cytokines, the unintended consequences for host defense and tumor surveillance and potential ways in which these therapies can be applied to treat additional immune disorders.
DOI: 10.1038/nm.3895
PubMed: 26121196
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B51
- to stream PubMed, to step Curation: 002A79
- to stream PubMed, to step Checkpoint: 002A79
- to stream Ncbi, to step Merge: 002772
- to stream Ncbi, to step Curation: 002772
- to stream Ncbi, to step Checkpoint: 002772
- to stream Main, to step Merge: 002C78
- to stream Main, to step Curation: 002C78
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.</title>
<author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name>
<affiliation wicri:level="1"><nlm:affiliation>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bowman, Edward P" sort="Bowman, Edward P" uniqKey="Bowman E" first="Edward P" last="Bowman">Edward P. Bowman</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Palo Alto, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Palo Alto, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcelwee, Joshua J" sort="Mcelwee, Joshua J" uniqKey="Mcelwee J" first="Joshua J" last="Mcelwee">Joshua J. Mcelwee</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><nlm:affiliation>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Casanova, Jean Laurent" sort="Casanova, Jean Laurent" uniqKey="Casanova J" first="Jean-Laurent" last="Casanova">Jean-Laurent Casanova</name>
<affiliation wicri:level="3"><nlm:affiliation>1] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. [2] Howard Hughes Medical Institute, New York, New York, USA. [3] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France. [4] Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France. [5] Paris Descartes University, Imagine Institute, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. [2] Howard Hughes Medical Institute, New York, New York, USA. [3] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France. [4] Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France. [5] Paris Descartes University, Imagine Institute, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Andrea M" sort="Cooper, Andrea M" uniqKey="Cooper A" first="Andrea M" last="Cooper">Andrea M. Cooper</name>
<affiliation wicri:level="2"><nlm:affiliation>Trudeau Institute, Inc., Saranac Lake, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Trudeau Institute, Inc., Saranac Lake, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cua, Daniel J" sort="Cua, Daniel J" uniqKey="Cua D" first="Daniel J" last="Cua">Daniel J. Cua</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Palo Alto, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Palo Alto, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26121196</idno>
<idno type="pmid">26121196</idno>
<idno type="doi">10.1038/nm.3895</idno>
<idno type="wicri:Area/PubMed/Corpus">002B51</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B51</idno>
<idno type="wicri:Area/PubMed/Curation">002A79</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A79</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A79</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A79</idno>
<idno type="wicri:Area/Ncbi/Merge">002772</idno>
<idno type="wicri:Area/Ncbi/Curation">002772</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002772</idno>
<idno type="wicri:Area/Main/Merge">002C78</idno>
<idno type="wicri:Area/Main/Curation">002C78</idno>
<idno type="wicri:Area/Main/Exploration">002C78</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.</title>
<author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name>
<affiliation wicri:level="1"><nlm:affiliation>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bowman, Edward P" sort="Bowman, Edward P" uniqKey="Bowman E" first="Edward P" last="Bowman">Edward P. Bowman</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Palo Alto, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Palo Alto, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcelwee, Joshua J" sort="Mcelwee, Joshua J" uniqKey="Mcelwee J" first="Joshua J" last="Mcelwee">Joshua J. Mcelwee</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><nlm:affiliation>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Casanova, Jean Laurent" sort="Casanova, Jean Laurent" uniqKey="Casanova J" first="Jean-Laurent" last="Casanova">Jean-Laurent Casanova</name>
<affiliation wicri:level="3"><nlm:affiliation>1] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. [2] Howard Hughes Medical Institute, New York, New York, USA. [3] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France. [4] Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France. [5] Paris Descartes University, Imagine Institute, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. [2] Howard Hughes Medical Institute, New York, New York, USA. [3] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France. [4] Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France. [5] Paris Descartes University, Imagine Institute, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Andrea M" sort="Cooper, Andrea M" uniqKey="Cooper A" first="Andrea M" last="Cooper">Andrea M. Cooper</name>
<affiliation wicri:level="2"><nlm:affiliation>Trudeau Institute, Inc., Saranac Lake, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Trudeau Institute, Inc., Saranac Lake, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cua, Daniel J" sort="Cua, Daniel J" uniqKey="Cua D" first="Daniel J" last="Cua">Daniel J. Cua</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck Research Laboratories, Palo Alto, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Palo Alto, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature medicine</title>
<idno type="eISSN">1546-170X</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Immunity</term>
<term>Immunologic Surveillance</term>
<term>Inflammation (immunology)</term>
<term>Inflammation (pathology)</term>
<term>Interleukin-12 (antagonists & inhibitors)</term>
<term>Interleukin-12 (metabolism)</term>
<term>Interleukin-23 (antagonists & inhibitors)</term>
<term>Interleukin-23 (metabolism)</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Immunité</term>
<term>Inflammation (anatomopathologie)</term>
<term>Inflammation (immunologie)</term>
<term>Interleukine-12 (antagonistes et inhibiteurs)</term>
<term>Interleukine-12 (métabolisme)</term>
<term>Interleukine-23 (antagonistes et inhibiteurs)</term>
<term>Interleukine-23 (métabolisme)</term>
<term>Surveillance immunologique</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-12</term>
<term>Interleukin-23</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-12</term>
<term>Interleukine-23</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Inflammation</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-12</term>
<term>Interleukin-23</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Interleukine-12</term>
<term>Interleukine-23</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Inflammation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Immunity</term>
<term>Immunologic Surveillance</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Immunité</term>
<term>Surveillance immunologique</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell-mediated responses in inflammation for more than a decade after it was first identified. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Ustekinumab, a therapeutic agent targeting both cytokines, was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders. Here we discuss the therapeutic rationale for targeting these cytokines, the unintended consequences for host defense and tumor surveillance and potential ways in which these therapies can be applied to treat additional immune disorders.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Massachusetts</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name>
</noRegion>
<name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Bowman, Edward P" sort="Bowman, Edward P" uniqKey="Bowman E" first="Edward P" last="Bowman">Edward P. Bowman</name>
</region>
<name sortKey="Cooper, Andrea M" sort="Cooper, Andrea M" uniqKey="Cooper A" first="Andrea M" last="Cooper">Andrea M. Cooper</name>
<name sortKey="Cua, Daniel J" sort="Cua, Daniel J" uniqKey="Cua D" first="Daniel J" last="Cua">Daniel J. Cua</name>
<name sortKey="Mcelwee, Joshua J" sort="Mcelwee, Joshua J" uniqKey="Mcelwee J" first="Joshua J" last="Mcelwee">Joshua J. Mcelwee</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Casanova, Jean Laurent" sort="Casanova, Jean Laurent" uniqKey="Casanova J" first="Jean-Laurent" last="Casanova">Jean-Laurent Casanova</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:26121196 |texte= IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26121196" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |